Logo

Garry Menzel

Aug 07, 2008
Premium
Regulus Therapeutics said that it has named Garry Menzel as executive vice president of corporate development and finance.
 
Menzel previously served as managing director for Credit Suisse. Before that, he was a managing director of Goldman Sachs’ healthcare group. He holds a PhD in molecular biology from the University of Cambridge and an MBA from the Stanford Graduate School of Business.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.